Evidence map›Paper›PMID 40994906›Full record

ArticleGynecologic oncology reports2025

Severe hemorrhage in choriocarcinoma: three scenarios and treatment strategies.

J Altmann, D Dimitrova, J Sehouli

Abstract read
In one paragraph

Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

J AltmannDepartment of Gynecology with Center of Oncological Surgery, Charité University Hospital Berlin, Germany.
D DimitrovaDepartment of Gynecology with Center of Oncological Surgery, Charité University Hospital Berlin, Germany.
J SehouliDepartment of Gynecology with Center of Oncological Surgery, Charité University Hospital Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Massive hemorrhage originating from the primary tumor site or metastases is a feared complication of choriocarcinoma. We present three cases of severe hemorrhage in patients with gestational choriocarcinoma and their clinical management. Case series: The first case is a 27-year old woman, who presented with acute hepatic hemorrhage due to metastases of choriocarcinoma 5 months after the birth of her first child. After abdominal packing via laparotomy and transfer of the patient in stable condition to our intensive care unit embolization of several hepatic arteries was performed by interventional angiography. The second case, a 28-year old primipara, presented with hemoperitoneum as a result of uterus perforation by choriocarcinoma. Surgical sutures of the perforated lesion were applied via laparotomy, preserving the uterus. The third case is a 28-year old primigravida with massive vaginal hemorrhage of a choriocarcinoma with pulmonary metastases. Stabilization of the bleeding was achieved by embolization of uterine arteries.All patients were classified as high-risk (FIGO classification) gestational choriocarcinoma and received EMA/CO chemotherapy until ßHCG reached normal levels as well as up to three additional cycles as consolidation. To date, all patients are in remission. Conclusion: In case of severe hemorrhage in patients with choriocarcinoma a skilled interdisciplinary team is needed. In case of acute hemorrhage in choriocarcinoma embolization of arteries should be preferred since these are safe and effective measures. In the vast majority of cases fertility-preserving strategies can safely be applied. Hysterectomy is not recommended as first-line treatment.

Identifiers

PMID40994906
PMCPMC12454301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.